A long-term follow-up of safety and clinical efficacy of NTCELL® [Immunoprotected (Alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease.

MLA

Mulroy, Eoin, et al. “A Long-Term Follow-up of Safety and Clinical Efficacy of NTCELL® [Immunoprotected (Alginate-Encapsulated) Porcine Choroid Plexus Cells for Xenotransplantation] in Patients with Parkinson’s Disease.” Parkinsonism & Related Disorders, vol. 82, Jan. 2021, pp. 128–32. EBSCOhost, https://doi.org/10.1016/j.parkreldis.2020.12.005.

APA

Mulroy, E., Snow, B., Bok, A., Simpson, M., Smith, A., Taylor, K. M., Lockhart, M., Lam, B. B. J., Frampton, C., Finucane, G., Schweder, P., Chen, B., McMahon, A., & Macdonald, L. (2021). A long-term follow-up of safety and clinical efficacy of NTCELL® [Immunoprotected (Alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson’s disease. Parkinsonism & Related Disorders, 82, 128–132. https://doi.org/10.1016/j.parkreldis.2020.12.005

Chicago

Mulroy, Eoin, Barry Snow, Arnold Bok, Mark Simpson, Andrew Smith, Kenneth M Taylor, Michelle Lockhart, et al. 2021. “A Long-Term Follow-up of Safety and Clinical Efficacy of NTCELL® [Immunoprotected (Alginate-Encapsulated) Porcine Choroid Plexus Cells for Xenotransplantation] in Patients with Parkinson’s Disease.” Parkinsonism & Related Disorders 82 (January): 128–32. doi:10.1016/j.parkreldis.2020.12.005.